Literature DB >> 24492252

PharmGKB summary: very important pharmacogene information for UGT1A1.

Julia M Barbarino1, Cyrine E Haidar, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24492252      PMCID： PMC4091838          DOI： 10.1097/FPC.0000000000000024

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  89 in total

Review 1.  Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity.

Authors:  I M Arias; L M Gartner; M Cohen; J B Ezzer; A J Levi
Journal:  Am J Med       Date:  1969-09       Impact factor: 4.965

2.  Crigler-Najjar syndrome types I and II. Clinical experience--King's College Hospital 1972-1978. Phenobarbitone, phototherapy and liver transplantation.

Authors:  S Pett; A P Mowat
Journal:  Mol Aspects Med       Date:  1987

Review 3.  The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996.

Authors:  S O'Reilly; E K Rowinsky
Journal:  Crit Rev Oncol Hematol       Date:  1996-09       Impact factor: 6.312

4.  Assignment of the human UDP glucuronosyltransferase gene (UGT1A1) to chromosome region 2q37.

Authors:  H H van Es; A Bout; J Liu; L Anderson; A M Duncan; P Bosma; R Oude Elferink; P L Jansen; J R Chowdhury; E Schurr
Journal:  Cytogenet Cell Genet       Date:  1993

5.  Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.

Authors:  Y Kawato; M Aonuma; Y Hirota; H Kuga; K Sato
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

6.  Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man.

Authors:  P J Bosma; J Seppen; B Goldhoorn; C Bakker; R P Oude Elferink; J R Chowdhury; N R Chowdhury; P L Jansen
Journal:  J Biol Chem       Date:  1994-07-08       Impact factor: 5.157

7.  Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

Authors:  E Beutler; T Gelbart; A Demina
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

8.  Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium.

Authors:  C P Strassburg; N Nguyen; M P Manns; R H Tukey
Journal:  Mol Pharmacol       Date:  1998-10       Impact factor: 4.436

9.  Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase.

Authors:  J Seppen; P J Bosma; B G Goldhoorn; C T Bakker; J R Chowdhury; N R Chowdhury; P L Jansen; R P Oude Elferink
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

10.  The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.

Authors:  P J Bosma; J R Chowdhury; C Bakker; S Gantla; A de Boer; B A Oostra; D Lindhout; G N Tytgat; P L Jansen; R P Oude Elferink
Journal:  N Engl J Med       Date:  1995-11-02       Impact factor: 91.245
View more
  44 in total

1.  Pharmacogenomics meets precision cardio-oncology: is there synergistic potential?

Authors:  Jennifer K Hockings; Jessica A Castrillon; Feixiong Cheng
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

2.  Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment.

Authors:  Marzia Del Re; Tiziana Latiano; Leonardo Fidilio; Giuliana Restante; Franco Morelli; Evaristo Maiello; Romano Danesi
Journal:  EPMA J       Date:  2017-03-07       Impact factor: 6.543

Review 3.  Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.

Authors:  Celia N Sanchez-Dominguez; Hugo L Gallardo-Blanco; Mauricio A Salinas-Santander; Rocio Ortiz-Lopez
Journal:  Exp Ther Med       Date:  2018-05-18       Impact factor: 2.447

4.  A physiome interoperability roadmap for personalized drug development.

Authors:  Simon Thomas; Katherine Wolstencroft; Bernard de Bono; Peter J Hunter
Journal:  Interface Focus       Date:  2016-04-06       Impact factor: 3.906

5.  DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.

Authors:  Felicia Stefania Falvella; Stefania Cheli; Antonia Martinetti; Cristina Mazzali; Roberto Iacovelli; Claudia Maggi; Manuela Gariboldi; Marco Alessandro Pierotti; Maria Di Bartolomeo; Elisa Sottotetti; Roberta Mennitto; Ilaria Bossi; Filippo de Braud; Emilio Clementi; Filippo Pietrantonio
Journal:  Br J Clin Pharmacol       Date:  2015-06-22       Impact factor: 4.335

6.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

7.  PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics.

Authors:  Maria Alvarellos; Chantal Guillemette; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2018-05       Impact factor: 2.089

8.  Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.

Authors:  Anushka Naidoo; Veron Ramsuran; Maxwell Chirehwa; Paolo Denti; Helen McIlleron; Kogieleum Naidoo; Nonhlanhla Yende-Zuma; Ravesh Singh; Sinaye Ngcapu; Mamoonah Chaudhry; Michael S Pepper; Nesri Padayatchi
Journal:  Pharmacogenomics       Date:  2017-12-06       Impact factor: 2.533

9.  Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.

Authors:  C F Spraggs; L R Parham; L P Briley; L Warren; L S Williams; D J Fraser; Z Jiang; Z Aziz; S Ahmed; G Demetriou; A Mehta; N Jackson; J Byrne; M Andersson; M Toi; L Harris; J Gralow; J A Zujewski; R Crescenzo; A Armour; E Perez; M Piccart
Journal:  Pharmacogenomics J       Date:  2017-08-08       Impact factor: 3.550

10.  Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimer's Disease.

Authors:  Yijun Pan; Kotaro Omori; Izna Ali; Masanori Tachikawa; Tetsuya Terasaki; Kim L R Brouwer; Joseph A Nicolazzo
Journal:  Mol Pharm       Date:  2018-08-22       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.